Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 10
2021 8
2022 2
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Influenza and Covid-19 Vaccination in 2023: a descriptive analysis in two Italian Research and Teaching Hospitals. Is the On-Site strategy effective?
Perrone PM, Villa S, Raciti GM, Clementoni L, Vegro V, Scovenna F, Altavilla A, Tomoiaga AM, Beltrami V, Bruno I, Vaccargiu M, Astorri E, Tiwana N, Letzgus M, Schulz PJ, Pregliasco FE, Castaldi S. Perrone PM, et al. Among authors: villa s. Ann Ig. 2024 Mar 21. doi: 10.7416/ai.2024.2606. Online ahead of print. Ann Ig. 2024. PMID: 38525974 Free article.
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.
Lombardi A, Villa S, Colaneri M, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F, Bassetti M, Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A; “COVID 19 NETWORK”. Lombardi A, et al. Among authors: villa s. J Infect Public Health. 2024 Mar;17(3):467-473. doi: 10.1016/j.jiph.2023.12.026. Epub 2024 Jan 17. J Infect Public Health. 2024. PMID: 38262085 Free article.
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
Global Tuberculosis Network and TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalón C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, Muñoz E, Muñoz C, Navarro I, Pizarro R, Cristina Sánchez GP, Vergara Riquelme MS, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillot ME, Rodriguez P, Salinas AS, Taiba C, Valdés JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Victoria Plaza R, Tello Hoyos KY, Cardoso-Landivar J, Van Den Boom M, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udwadia ZF, Alladio F, Angeli F, Calcagno A, Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi N, Sad… See abstract for full author list ➔ Global Tuberculosis Network and TB/COVID-19 Global Study Group, et al. Among authors: villa s. Eur Respir J. 2023 Nov 29;62(5):2300925. doi: 10.1183/13993003.00925-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37827576 Free PMC article.
The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.
Canuti M, Monti MC, Bobbio C, Muscatello A, Muheberimana T, Baldi SL, Blasi F, Canetta C, Costantino G, Nobili A, Peyvandi F, Tettamanti M, Villa S, Aliberti S, Raviglione MC, Gori A, Bandera A; COVID-19 Network Study Group. Canuti M, et al. Among authors: villa s. Front Med (Lausanne). 2023 Sep 7;10:1260950. doi: 10.3389/fmed.2023.1260950. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37746083 Free PMC article.
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, Tonizzo A, Fava M, Valzano AG, Morlacchi LC, Donato MF, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A. Lombardi A, et al. Among authors: villa s. Biomedicines. 2023 May 26;11(6):1540. doi: 10.3390/biomedicines11061540. Biomedicines. 2023. PMID: 37371635 Free PMC article.
Web-based surveillance of respiratory infection outbreaks: retrospective analysis of Italian COVID-19 epidemic waves using Google Trends.
Porcu G, Chen YX, Bonaugurio AS, Villa S, Riva L, Messina V, Bagarella G, Maistrello M, Leoni O, Cereda D, Matone F, Gori A, Corrao G. Porcu G, et al. Among authors: villa s. Front Public Health. 2023 May 18;11:1141688. doi: 10.3389/fpubh.2023.1141688. eCollection 2023. Front Public Health. 2023. PMID: 37275497 Free PMC article.
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study.
Biscarini S, Villa S, Genovese C, Tomasello M, Tonizzo A, Fava M, Iannotti N, Bolis M, Mariani B, Valzano AG, Morlacchi LC, Donato F, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A, Lombardi A. Biscarini S, et al. Among authors: villa s. Biomedicines. 2022 Aug 18;10(8):2002. doi: 10.3390/biomedicines10082002. Biomedicines. 2022. PMID: 36009549 Free PMC article.
31 results